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A B S T R A C T   
Objectives: Robust economic evaluations are needed to identify efficient strategies for lung cancer prevention that 
combine brief and intensive smoking cessation intervention programmes with screening using low-dose 
computed tomography (LDCT) at different ages, frequencies, and coverages. We aimed to assess the cost- 
effectiveness of smoking cessation approaches combined with lung cancer screening in the European context 
at a population level from a societal perspective. 
Materials and Methods: A microsimulation model that describes the natural history of lung cancer and in-
corporates several prevention strategies was developed. Discounted lifetime QALYs and costs at a rate of 3% were 
used to calculate incremental cost-effectiveness ratios, defined as additional costs in 2017 Euros per QALY 
gained. 
Results: Smoking cessation interventions reduce the incidence of lung cancer by 8%-46% and are consistently 
more effective and cost-effective when starting at younger ages. Screening reduces lung cancer mortality by 1%- 
24% and is generally less effective and more costly than smoking cessation interventions. The most cost-effective 
strategy would be to implement intensive smoking cessation interventions at ages 35, 40 and 45, combined with 
screening every three years between the ages of 55 and 65. 
Conclusions: Combining smoking cessation interventions with LDCT screening is a very attractive prevention 
strategy that substantially diminishes the burden of lung cancer. These combined prevention strategies, espe-
cially when providing several intensive interventions for smoking cessation at early ages, are more cost-effective 
than both approaches separately and allow for a more intensified LDCT without losing efficiency.   
1. Introduction 
Despite some global decline, lung cancer continues to present a huge 
challenge for health policies with over 470 thousand cases reported 
annually in Europe. This figure represents approximately 12% of all 
cancers, 65% of which are diagnosed in men[1]. Since the 1930s, lung 
cancer has gradually increased, mostly caused by changes in the prev-
alence of tobacco consumption, and has emerged as one of the most 
important cancers worldwide[2]. 
The current burden of lung cancer is determined by the tobacco 
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consumption that the population had about 30 years ago[3]. Thus, the 
way to reduce the impact of lung cancer on the population must be 
approached from two fronts. On the one hand, to reduce the future 
incidence of the disease through cessation strategies and, on the other 
hand, to avoid mortality of those who already have a high risk of cancer 
[4]. This latter group would be made up of subjects who have main-
tained very high tobacco consumption and have reached the age at 
which lung cancer is most frequent, even those who have quit smoking 
in the last 10–15 years. Primary prevention would have little or no 
benefit in these people and early detection would be the only alternative 
to reduce mortality. Early detection with annual low-dose computed 
tomography (LDCT) has been shown to significantly reduce lung cancer 
mortality in high-risk patients[5]. However, the optimal timing of lung 
cancer screening intervals is still an ongoing debate[6]. In 2017, a task 
force of the European Society of Thoracic Surgeons (ESTS) strongly 
recommended the implementation of screening programmes in Euro-
pean countries and issued ten general recommendations concerning 
screening with computed tomography[7]. All studies on lung cancer 
prevention have focused either on smoking cessation or on early 
detection. Only some authors include smoking cessation in the context 
of early detection for ethical reasons without considering what the 
utility would be in reducing the incidence of lung cancer in patients of 
advanced age. Furthermore, smoking cessation in patients undergoing 
LDCT screening remains unclear and no studies compared drug-based 
treatment to smoking cessation counselling[8]. 
Health policy decision-makers are increasingly aware of the impor-
tance of taking efficiency criteria into account. Budgetary constraints in 
the different health systems mean that not all available interventions can 
be included in healthcare plans. In this context, it is becoming common 
in public health systems to use outcomes from economic evaluations, 
such as cost-effectiveness analyses, to inform about decisions on the 
allocation of healthcare resources[9]. The dual aim of any healthcare 
prevention strategy is to improve population health, while at the same 
time staying within the bounds of economic constraints. Health eco-
nomic evaluations are key to enabling health benefits to be maximized 
with an efficient use of resources. 
This study presents a cost-effectiveness analysis of single and com-
bined primary and secondary preventive strategies for lung cancer at 
different times throughout life. The aim of the study was to identify 
which single or combined preventive choices are more cost-effective to 
reduce the burden of lung cancer in Spain. Since not all smokers would 
reach the same risk of lung cancer, we have prioritized individuals with 
a high risk of dying from lung cancer in the short term and individuals 
with a potential high risk of developing lung cancer in the medium term. 
In addition, since the prevalence of smoking in Spain is very different in 
men than in women, and consequently the incidence of and mortality 
from lung cancer are also very different, we decided to consider only 
men in this analysis. 
2. Material and methods 
2.1. Model 
A Markov-based microsimulation model was developed for 
describing the longitudinal progression of the natural history of lung 
cancer. Six mutually exclusive health states were considered: one 
healthy state in terms of lung cancer (Healthy); three lung cancer states: 
local (LC I-II), regional (LC IIIa) and distant (LC IIIb-IV), corresponding to 
stages I and II, stage IIIa, and stages IIIb and IV, respectively; death 
caused by lung cancer (LC death); and death by other causes (Other 
death) [Supplementary appendix Figure S1a]. This aggregation of the 
states in local, regional, and distant is a simplification of reality that 
favours obtaining some parameters, but which could have an uncertain 
impact on the results. Since the risk of lung cancer depends on the 
smoking habit (i.e. the Markov property is not fulfilled because future 
health states not only depend on the current health state), some parts of 
the model were microsimulated by adding certain functionalities to the 
Markov model (Smoking, Quitting and Survival) [Supplementary ap-
pendix Figure S1b]. The model follows a single theoretical cohort of 
100,000 men aged 35 in 1-month increments until they reach the age of 
80 or die. Forty simulations of the cohort for each strategy (see the 
Prevention strategies section) were performed to reflect a certain degree 
of variability in the parameters. Transition probabilities between the 
different health states are age-dependent and were divided into nine 
transition matrices corresponding to each age group in five-year in-
tervals ([35–40), …, [75–80)). Initial probabilities were extracted from 
published scientific literature and clinical trials, and subsequently cali-
brated to reproduce the male lung cancer burden in Spain. The model 
was coded in R using the Rcpp package[10] and C++[11]. For details on 
the modelling of the effect of smoking, the effect of quitting and the 
effect of diagnosis see the Supplementary appendix. 
2.2. Prevention strategies 
Three different intervention strategies were modelled. Two of them 
are focused on reducing smoking prevalence in the population with brief 
and intensive smoking cessation interventions, thereby reducing future lung 
cancer incidence and, consequently, mortality, while a third is an 
organized screening intervention strategy aimed at detecting lung can-
cer at earlier stages in a bid to reduce mortality. The brief intervention 
strategy for quitting smoking is based on the 5 A’s method developed by 
the Agency for Health Care Policy and Research in the United States 
[12]. In it, healthcare providers ask every patient about their tobacco 
use, advise smokers to quit, assess smokers’ willingness to make a quit 
attempt, assist smokers in their quit attempt and arrange follow-up 
contacts[13]. The intensive intervention for quitting smoking is a 
behavioural and drug-based treatment including follow-up contacts over 
a 12-month period. Smoking cessation interventions were evaluated 
assuming different periodicities (once, twice, and thrice in a lifetime) 
and starting age (35 or 55 years). Finally, the screening intervention was 
based on LDCT using different frequencies. The optimal frequency of 
screening is still controversial. Guidelines for screening have generally 
suggested annual, biennial or three consecutive annual scans[14], and 
actually health benefits and reduction in costs are unclear for less 
frequent intervals. In order to observe the health and economic impact 
of the screening frequency and the effect of smoking cessation in-
terventions on the reduction of lung cancer burden, several screening 
periodicities at different ages were evaluated. Specifically, these were 
once in a lifetime (at age 55), twice in a lifetime (at ages 55 and 56 or 55 
and 60) and thrice in a lifetime (at ages 55, 56, 57 or 55, 60 and 65), and 
every 1, 2, 3 and 4 years starting at age 55 (corresponding to twenty 
times, ten times, seven times and five times in a lifetime, respectively). 
We considered that interventions will be offered free of charge at the 
time of the routine visit to the physician. For this reason, we assumed 
that all patients would accept the interventions. 
The strategies evaluated in this project comprised combinations of 
these three interventions according to two risk groups based on the 
NLST trial[15]. The “highly at risk” group was defined as the population 
aged between 55 and 74 with a smoking history of ≥ 30 pack years. The 
“potentially at high risk” group was defined as the population aged <55 
(in the model a starting age of 35 was assumed) who, by the time they 
are 55, will have a smoking history of ≥ 30 pack years if they do not 
change their smoking consumption[16]. 
2.3. Input data, model parameters and assumptions 
The initial transition probabilities before calibration mimicking the 
baseline natural history of lung cancer and calibration targets were 
based on published data. The initial transitions between alive health 
states were extracted from Hinde et al.[17]. The initial transitions to the 
LC death state were based on the age-specific five-year relative survival 
rate calculated by EUROCARE, transformed into monthly intervals[18]. 
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We did not implicitly include recurrence after treatment in the model. 
However, mortality is captured in the 5-year relative survival rate used 
to calculate probability of death from lung cancer given that most dis-
ease recurrences will be before 5 years after treatment and most of the 
patients will die in this period[19]. The initial transitions to the Other 
death state were based on the age-specific risk of death calculated by the 
Spanish National Institute of Statistics (INE), transformed into monthly 
intervals[20]. The probability of survival following diagnosis by 
screening for each cancer stage was adapted from the American Cancer 
Society data[21]. These data were weighted by the distribution of both 
tumour type and cancer stage based on screening[22,23]. 
The data on cancer incidence and mortality used for calibration were 
provided by the International Agency for Research on Cancer (IARC) via 
the CANCERMondial database[24]. Specifically, the incidence data were 
drawn from Globocan[25], while the mortality data were extracted from 
the WHO Cancer Mortality Database[26]. For more details on model 
calibration, see Supplementary appendix. We defined the term coverage 
as the percentage of the eligible population at risk that have access to the 
program. In Spain, an average of 75% of the male population aged 
35–74 years old (66% at 35–54 and 89% at 55–74) is attended to by the 
Primary Health Care of the Spanish NHS and therefore, it is possible to 
identify their risk[27]. Around 25% of them are high-risk smokers (68% 
of smokers at age 35–54 and 25% of the current and former smokers at 
age 55–74), which gives us the eligible population, high-risk individuals 
residing in the territory who will have access to the interventions[28]. 
Specifically, the baseline coverage for smoking cessation interventions 
and screening was set at 18.69%[27,29]. The effectiveness of smoking 
cessation interventions and the sensitivity of LDCT screening was 
extracted from published literature[22,30–32]. 
The costs incurred for smoking cessation and screening programmes 
were obtained using various sources[30,33]. The cost incurred for post- 
diagnosis treatment was estimated with administrative data for patients 
with lung cancer in Catalonia (Spain) from a hospital perspective[34]. 
The aggregate cost for all stages was calculated as the mean over the first 
three years following diagnosis or up to death. This cost included (a) 
diagnosis (diagnostic tests, ambulatory and emergency visits, inpatient 
nights), (b) surgery (operating room and inpatient nights), (c) chemo-
therapy (day hospital and cytotoxic drugs), (d) radiotherapy (number of 
fractions), (e) other inpatient care (not related to diagnosis, surgery, 
chemotherapy or radiotherapy treatments for lung cancer, e.g., hospital 
admissions related to COPD or other comorbidities and palliative care), 
and (f) continuing care including recurrence (ambulatory and emer-
gency visits, tests, scans, biopsies, etc., made in the continuing phase) 
[34]. Some recurrence costs were included in the post-diagnosis treat-
ment if they occur within three years following diagnosis. In some 
studies, direct costs of lung cancer are estimated at approximately a 
quarter of the total cost, so healthcare costs were increased fourfold in 
order to add indirect costs and simulate cost-effectiveness from a soci-
etal perspective[35,36]. Health state utilities were extracted from pub-
lished literature[37,38]. 
Relevant input data including costs and utilities, and selected model 
parameters and intervention assumptions, are shown in Supplementary 
appendix Table S1. Influential data were varied in deterministic one- 
and two-way sensitivity analyses and probabilistic sensitivity analyses. 
2.4. Model outcomes and cost-effectiveness analysis 
Lifetime health outcomes predicted by the model for each strategy 
were expressed as quality-adjusted life years (QALYs), calculated by 
adding the time spent in each state multiplied by the respective utility. 
Costs are presented in euros (€) indexed at year 2017. Both health and 
economic outcomes were discounted at an annual rate of 3%[39]. Next, 
the incremental cost-effectiveness ratio (ICER) was calculated as the 
difference in cost between two strategies, divided by the difference in 
health effect (QALYs). It is represented as the incremental cost of a 
strategy associated with one additional QALY compared with another 
strategy. Deterministic and probabilistic sensitivity analyses were per-
formed to identify which input data, model parameters and assumptions 
were critical in driving a decision. 
The willingness-to-pay threshold is defined as between €22,000 and 
€25,000 per QALY [40]. This threshold is similar to that reported in 
other European countries[41]. 
3. Results 
3.1. Smoking cessation interventions alone 
Any of the smoking cessation interventions alone was systematically 
more effective when the age at which the intervention started was 
younger [Table 1 and Supplementary appendix Table S3]. The per-
centage reduction in lung cancer incidence and mortality was similar 
and varied from 1.6% to 5.4% at age 55 depending on the intervention 
(brief or intensive) and frequency, and from 3.5% to 11.9% at age 35. 
The brief intervention was more effective and saved money compared 
with no intervention, irrespective of age and frequency. The intensive 
intervention was also always more effective than no intervention and 
was cost-saving when started at age 35 and cost-effective at very low 
cost per QALY when started at age 55 compared with no intervention. 
The incremental cost-effectiveness analysis including only smoking 
cessation interventions indicated that having three rounds at ages 35, 40 
and 45 was cost-saving when using brief intervention and cost €7244 per 
QALY when using intensive intervention compared with the next most 
costly strategy after eliminating strategies that were dominated (more 
costly and less effective, or less cost-effective—higher ICERs—than more 
effective options) [Fig. 1]. The percentage reduction in lung cancer 
incidence and mortality was practically equal, reaching 7.6% for the 
brief intervention and around 12% for the intensive intervention. 
3.2. Screening alone 
Screening alone was more effective and more costly than no inter-
vention, irrespective of age and frequency, and generally less effective 
and more costly than smoking cessation interventions [Table 1 and 
Supplementary appendix Table S4]. Screening reduced lung cancer 
mortality by between 1% and 7% in the base case analysis depending on 
frequency. The incremental cost-effectiveness analysis that included 
screening-only strategies showed that screening once at age 55 would 
come in below the threshold at a cost of €17,352 per QALY compared 
with no intervention [Fig. 2]. Repeated LDCT screenings for more than 
10 years or over age 65 were dominated by screenings at younger ages or 
exceeded by far the cost-effectiveness threshold, not being cost- 
effective. Therefore, along with the large number of strategies 
included in the analysis, screening strategies were restricted to the age 
group 55–65 (data not shown). 
3.3. Combining smoking cessation and screening interventions 
Strategies combining smoking cessation interventions and screening 
achieved the greatest reduction in incidence and mortality, especially 
when the intervention involved three rounds of intensive intervention at 
ages 35, 40 and 45 [Table 1 and Supplementary appendix Table S7]. The 
percentage reduction in incidence was around 12% and lung cancer 
mortality varied between 12% and 18% depending on screening fre-
quency. The effect of smoking cessation interventions within the com-
bined strategies was critical because when more rounds of these 
interventions were included, the screening frequency (shorter intervals) 
was higher at nearly the same cost [Supplementary appendix]. If only 
one round of intensive intervention is implemented at age 35, the most 
cost-effective strategy is for this to be combined with screening every 1 
year from ages 55–65 at a cost of €23,687 per QALY compared with the 
next most costly strategy [Table 1 and Supplementary appendix, 
Table S5 and Figure S4]. If two rounds of intensive intervention are 
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implemented at ages 35 and 40, the most cost-effective strategy is for 
this to be combined with screening every 4 years from ages 55–65 at a 
cost of €24,171 per QALY compared with the next most costly strategy 
[Table 1, Supplementary appendix, Table S6 and Figure S5]. The most 
cost-effective strategy below the threshold was to perform three rounds 
of intensive intervention at ages 35, 40 and 45 combined with screening 
every three years between ages 55 and 65 at a cost of €21,703 per QALY 
compared with the next most costly strategy, and €4,732 per QALY 
compared with no intervention [Table 1, Fig. 3 and Supplementary 
appendix Table S7 and Figure S6]. Increasing the frequency of screening 
to every two years or decreasing the interval would be a dominated 
strategy. This would be the same as increasing the frequency of 
screening to once a year which would have an ICER of €46,376 per 
QALY, being cost-effective when compared with the next most costly 
strategy, or €13,213 per QALY with no intervention. Additional baseline 
analyses are included in the Supplementary appendix. 
3.4. Sensitivity analysis 
The deterministic and probabilistic sensitivity analyses shown in 
both the main manuscript and the supplemental appendix correspond to 
the most cost-effective strategy (3xISCI @35, 40 and 45+ 3y-SCR 
@55–65) compared to no intervention. The effect on cost-effectiveness 
of some parameters and assumptions is presented in Fig. 4. Interven-
tion coverage varied between 5% and 91%, where the latter figure 
corresponds to the maximum percentage of the smoking population 
aged 35–74 that could attend primary healthcare in Spain. Both smoking 
cessation and screening coverage have a high impact on the ICERs, but 
the effect is inverted (Supplementary appendix, Figure S7). The cost- 
effectiveness of the intervention became more substantial as the 
coverage of smoking cessation strategies was increased and less sub-
stantial as screening coverage was increased. Smoking cessation in-
terventions have more QALYs per unit of cost than screening when 
Table 1 
Percentage reduction in lung cancer incidence and mortality, costs, QALYs and incremental cost-effectiveness ratios for non-dominated strategies according to different 
analysis.   
% ASIR reduction1 % ASMR reduction2 Cost (€) QALYs ICER (€/QALY) 
No intervention –  – 1359  23.31187 – 
Smoking cessation intervention alone 
3x BSCI @35, 40, 45 7.6%  7.6% 1273  23.33337 cost-saving 
3x ISCI @35, 40, 45 11.8%  11.9% 1339  23.34246 €7,244 
Screening alone 
1x SCR @55 0%  0.9% 1457  23.31751 €17,352 
3x SCR @55, 60, 65 0%  2.4% 1591  23.32099 €25,441 
2y-SCR @55–65 0%  4.1% 1765  23.32543 €29,910 
1y-SCR @55–65 0%  7.4% 2156  23.33473 €34,877  
Combined once in a lifetime brief smoking cessation intervention at age 35 plus screening1 
1x BSCI @35+ 1xSCR @55 3.6%  4.3% 1415  23.32550 €4,079 
1x BSCI @35+ 2xSCR @55, 56 3.6%  4.9% 1506  23.32963 €22,171 
1x BSCI @35+ 3xSCR @55, 60, 65 3.5%  5.6% 1545  23.33061 €39,638 
1x BSCI @35+ 1y-SCR @55–65 3.7%  10.6% 2087  23.34255 €45,432  
Combined once in a lifetime intensive smoking cessation intervention at age 35 plus screening1 
1x ISCI @35+ 1xSCR @55 6.6%  7.4% 1445  23.33545 €3,653 
1x ISCI @35+ 3y-SCR @55–65 6.9%  9.3% 1571  23.33936 €32,249 
1x ISCI @35+ 1y-SCR @55–65 6.9%  13.4% 2090  23.35273 €38,774  
Combined twice in a lifetime brief smoking cessation intervention at age 35 & 40 plus screening1 
2x BSCI @35, 40+ 1xSCR @55 5.6%  6.2% 1390  23.33013 €1,675 
2x BSCI @35, 40+ 2xSCR @55, 60 5.7%  5.1% 1458  23.33352 €20,259 
2x BSCI @35, 40+ 2xSCR @55, 56 6.1%  7.1% 1472  23.33405 €25,585 
2x BSCI @35, 40+ 3xSCR @55, 56, 57 5.8%  7.3% 1555  23.33688 €29,459 
2x BSCI @35, 40+ 1y-SCR @55–65 6.0%  12.5% 2036  23.34664 €49,242  
Combined twice in a lifetime intensive smoking cessation intervention at age 35 & 40 plus screening1 
2x ISCI @35, 40+ 1xSCR @55 10.0%  7.4% 1434  23.33966 €2,703 
2x ISCI @35, 40+ 2xSCR @55, 60 9.9%  8.4% 1504  23.34328 €19,192 
2x ISCI @35, 40+ 4y-SCR @55–65 9.9%  8.8% 1561  23.34622 €19,567 
2x ISCI @35, 40+ 2y-SCR @55–65 10.2%  10.3% 1701  23.34738 €120,757 
2x ISCI @35, 40+ 1y-SCR @55–65 9.9%  13.4% 2064  23.35020 €128,704  
Combined thrice in a lifetime brief smoking cessation intervention at age 35, 40 & 45 plus screening1 
3x BSCI @35, 40, 45+ 1xSCR @55 7.3%  8.0% 1366  23.33397 €304 
3x BSCI @35, 40, 45+ 2xSCR @55, 60 7.8%  9.1% 1432  23.33812 €15,971 
3x BSCI @35, 40, 45+ 4y-SCR @55–65 7.6%  9.7% 1492  23.34003 €31,436 
3x BSCI @35, 40, 45+ 1y-SCR @55–65 7.6%  13.9% 1998  23.35052 €48,191  
Combined thrice in a lifetime intensive smoking cessation intervention at age 35, 40 & 45 plus screening1 
3x ISCI @35, 40, 45+ 1xSCR @55 11.5%  11.9% 1430  23.34431 €2,173 
3x ISCI @35, 40, 45+ 2xSCR @55, 60 11.9%  13.1% 1491  23.34894 €13,195 
3x ISCI @35, 40, 45+ 3y-SCR @55–65 11.7%  13.6% 1550  23.35219 €18,215 
3x ISCI @35, 40, 45+ 1y-SCR @55–65 11.9%  17.9% 2028  23.36250 €46,378  
All strategies 
3x BSCI @35&40&45 7.6%  7.6% 1273  23.33337 cost-saving 
3x ISCI @35&40&45 11.8%  11.9% 1339  23.34246 €7,244 
3x ISCI @35&40&45+ 3y-xSCR-HR @55–65 11.7%  13.6% 1550  23.35219 €21,703 
3x ISCI @35&40&45+ 1y-xSCR-HR @55–65 11.9%  17.9% 2028  23.36250 €46,376  
1 Percentage of age standardized incidence rate (ASIR) reduction compared to no intervention; 2Percentage of age-standardized mortality rate (ASMR) reduction 
compared to no intervention; 3Once in a lifetime (1x), twice in a lifetime (2x), thrice in a lifetime (3x), every year (1y), every 2 years (2y), every 3 years (3y), every 4 
years (4y) 
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coverage improves, indicating that an increase in screening coverage 
among a population with lower risk is not efficient. The influence of the 
probability of survival was marginal when varied between half and 
double. The uncertainty of the cost of screening was higher than that of 
the cost of smoking cessation strategies, and a 75% decrease in the costs 
of both interventions would lead to cost-savings. A 75% increase in the 
effectiveness of the intensive smoking cessation intervention has a great 
impact on ICER, approaching €20,000 per QALY gained. However, the 
same increase in screening sensitivity is minimal. In all cases, the cost 
per QALY would not exceed the willingness-to-pay threshold (€22,000- 
€25,000 per QALY), except for the interaction between the effectiveness 
of the intensive intervention and the sensitivity of the screening. A 75% 
decrease in both effectiveness of the intensive intervention and sensi-
tivity of screening would make the strategy no longer cost-effective 
compared to no intervention. Additional deterministic and probabi-
listic sensitivity analyses are included in the results section of the 
Fig. 1. Cost-effectiveness efficiency frontier for smoking cessation intervention-alone strategies by frequency and age. Strategies lying on the efficiency curve 
dominate those lying to the right of the curve because they are more effective, and either cost less or have a more attractive cost-effectiveness ratio than the next 
best strategy. 
Fig. 2. Cost-effectiveness efficiency frontier for screening-only strategies by frequency and age. Strategies lying on the efficiency curve dominate those lying to the 
right of the curve because they are more effective, and either cost less or have a more attractive cost-effectiveness ratio than the next best strategy. 
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Our results show that an intensive intervention for smoking cessation 
at ages 35, 40 and 45 combined with screening using LDCT every three 
years at ages between 55 and 65 years is a cost-effective strategy with an 
increase of €21,703 per QALY compared with intensive smoking cessa-
tion intervention alone, and €4732 per QALY compared with no inter-
vention. In Europe, it is estimated that 477,534 new cases of lung cancer 
were diagnosed in 2018, more than 391,000 of which were caused by 
smoking, and up to 184,000 of which, and a similar number of deaths, 
might have been avoided with the implementation of this strategy. Ac-
cording to the country scenario, a long series of efficient strategies can 
Fig. 3. Cost-effectiveness efficiency frontier for combined smoking cessation intervention applied three times plus screening by frequency and age. Strategies lying 
on the efficiency curve dominate those lying to the right of the curve because they are more effective, and either cost less or have a more attractive cost-effectiveness 
ratio than the next best strategy. 
Fig. 4. One- and two-way sensitivity analysis for the intensive cessation smoking intervention strategy at ages 35, 40, 45 plus screening every 3 years from ages 
55–65 compared to no intervention. 
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be adapted to reduce lung cancer incidence and mortality. A simple 5 A’s 
smoking cessation strategy administered three times among the poten-
tially high-risk population would save money or have a low overall cost 
depending on the coverage. This strategy might avoid between 8% and 
31% of cases and deaths, covering at least 19% of smokers and ex- 
smokers under age 55 with a smoking history of ≥ 30 pack-years. A 
similar approach using intensive smoking cessation methods would 
result in an additional reduction of 4%-16%. Although quitting smoking 
at any age can lower the risk of lung cancer, the risk is still higher than 
that for people who never smoked. Therefore, some people such as 
heavy smokers could benefit from screening. Including screening with 
LDCT would not have a significant impact on incidence but could add 
between 2% and 24% to the reduction in lung cancer mortality 
depending on the combination of smoking cessation interventions used, 
their frequency and coverage. Therefore, early smoking cessation in-
terventions and screening of heavy and older smokers should be 
considered as complementary strategies and not as two mutually 
exclusive prevention alternatives. 
To our knowledge, there is no European study available on the cost- 
effectiveness of lung cancer prevention strategies combining smoking 
cessation interventions and LDCT screening. Four cost-effectiveness 
analyses for lung cancer prevention have been performed in Europe; 
however, none of them combined smoking cessation interventions and 
secondary prevention with LDCT[17,42–44]. Regarding the economic 
evaluations for lung cancer screening performed in non-European 
countries, the comparison of the cost-effectiveness models may be 
hampered by methodological heterogeneity. However, all of them 
assessed the implementation of LDCT compared with no screening and 
only three studies included smoking cessation activities with a single 
course of nicotine replacement or varenicline. All three studies 
concluded that lung cancer screening with LDCT appears to be cost- 
effective and that a supplementary smoking cessation programme can 
improve outcomes[45–47]. To our knowledge, no articles have been 
published including both brief and intensive smoking cessation inter-
vention programmes separately or in combination with screening using 
LDCT and evaluating a wide range of combinations depending on age, 
frequency, and coverage. 
There are several inherent limitations to simulation models that have 
often been mentioned, such as the uncertainty of the input parameters or 
certain methodological assumptions[48]. Attempts have been made to 
address these issues using the best available data in the literature with 
consensus decisions based on an expert lung cancer panel, calibrating 
the model to reproduce the real scenario as accurately as possible, and 
performing sensitivity analyses. The lack of crucial information on 
certain aspects of the natural history of lung cancer is also an important 
limitation. Furthermore, our model did not consider the potential for 
overdiagnosis or lead-time bias. Overdiagnosis may lead to unnecessary 
treatment of asymptomatic patients, and thereby increase costs with few 
health benefits. An adjusted model for overdiagnosis would improve 
cost-effectiveness of LDCT screening. Lead-time bias may extend the 
time between diagnosis and death but not the survival, and thereby 
potentially decrease costs with some additional health benefits. An 
adjusted model for lead-time bias would worsen the cost-effectiveness of 
LDCT screening. It is uncertain how these two outcomes offset each 
other. In our model, the impact on cost-effectiveness of the two biases 
would be lessened because we considered an average cost of treatment 
for all stages, and therefore, only changes would occur in the QALYs. 
The study focused on the risk of lung cancer, disregarding all multiple 
benefits of smoking cessation interventions and LDCT screening in 
reducing or detecting tumours of other locations or pulmonary or car-
diovascular disease. Both smoking cessation interventions and screening 
would have been more cost-effective if we had accounted for the QALYs 
gained through preventing these illnesses. Even with these limitations, 
simulation models are a useful resource and are commonly used to 
address important health policy issues that cannot be explored through 
experimental studies[9]. These results can help healthcare decision- 
makers to make the most efficient choices concerning this critical dis-
ease, together with their associated costs. As smoking prevalence and its 
attributable disease burden change over time, and new information 
becomes available, it will be important to reassess the model. The ade-
quacy of the screening interval and the age range according to nodule 
specifications, as well as the calibration and evaluation of the optimal 
strategies in women will also be of crucial importance in next steps. 
Despite global efforts to control tobacco consumption in many 
countries with the adoption of the WHO Framework Convention on 
Tobacco Control (WHO FCTC) (first ratified by 40 states in 2005, and 
then by 53 states and the European Union in 2013), there is still a great 
deal of work to be done in this field. Smoking remains the scourge of 
worldwide cancer statistics and several other diseases. The use of price 
and tax measures, and state intervention in the tobacco market via a 
variety of actions, are necessary but not sufficient. The provision of 
smoking cessation interventions is still scarce in Spain. Although brief 
smoking cessation intervention is increasing, the 5 A’s steps are not fully 
implemented and information about tobacco consumption is not sys-
tematically recorded. Regarding intensive smoking cessation interven-
tion, the available programmes are voluntarily implemented and are not 
usually included in the public service portfolio[49]. The implementation 
of smoking cessation programmes using any of the described ap-
proaches, whether alone or in combination with screening using LDCT, 
can substantially reduce lung cancer mortality. Our model predicts that 
for every 140 smokers or former smokers screened every three years, 
lung cancer mortality can be reduced by one. This number shrinks to one 
in 26 on adding smoking cessation interventions via intensive inter-
vention at early ages, assuming coverage of smokers and former smokers 
currently attending the public health system only. If the entire smoking 
population were included, one lung cancer death could be avoided by 
intervening on 7 smokers or former smokers with the combined strategy. 
More precise screening eligibility criteria may help to further 
improve the effectiveness and cost-effectiveness of these strategies in the 
near future. However, the need to drastically reduce lung cancer 
morbidity and mortality is already urgent and implementing those 
intervention strategies already available that have been shown to be 
effective and efficient in Europe is of the highest importance to achieve 
more sustainable health systems 
5. Conclusion 
As indicated by the WHO, 90% of lung cancers could be avoided by 
eliminating tobacco use[50]. However, screening with LDCT is the only 
approach to avoid mortality of those who already have a high risk of 
cancer. A long-term organized approach combining primary prevention 
with smoking cessation interventions and secondary prevention with 
LDCT screening would result in a large decrease in the burden of lung 
cancer in the near future. These combined prevention strategies, espe-
cially when providing several intensive interventions for smoking 
cessation at early ages, are more cost-effective than both approaches 
separately and allow for a more intensified LDCT screening without 
losing efficiency. Spain is currently in the IV phase of the epidemic curve 
and shows similar behaviour to the rest of the countries of southern 
Europe[45]. The similarity in the regions anticipates that these results 
will also be of more general interest. It is of vital importance to allocate 
resources efficiently at a time of health and economic crisis like now, 
where health policymakers must decide in circumstances of large un-
certainty and face difficult trade-offs given the health, economic and 
social challenges that arise. 
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